HomeCompareBRCPF vs ABBV

BRCPF vs ABBV: Dividend Comparison 2026

BRCPF yields 78.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRCPF wins by $5423826956248.81M in total portfolio value
10 years
BRCPF
BRCPF
● Live price
78.90%
Share price
$4.07
Annual div
$3.21
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5423826956248.91M
Annual income
$5,410,653,946,133,164,000.00
Full BRCPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BRCPF vs ABBV

📍 BRCPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRCPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRCPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRCPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCPF
Annual income on $10K today (after 15% tax)
$6,706.89/yr
After 10yr DRIP, annual income (after tax)
$4,599,055,854,213,189,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BRCPF beats the other by $4,599,055,854,213,168,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCPF + ABBV for your $10,000?

BRCPF: 50%ABBV: 50%
100% ABBV50/50100% BRCPF
Portfolio after 10yr
$2711913478124.51M
Annual income
$2,705,326,973,066,594,300.00/yr
Blended yield
99.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BRCPF
No analyst data
Altman Z
1.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCPF buys
0
ABBV buys
0
No recent congressional trades found for BRCPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRCPFABBV
Forward yield78.90%3.06%
Annual dividend / share$3.21$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$5423826956248.91M$102.3K
Annual income after 10y$5,410,653,946,133,164,000.00$24,771.77
Total dividends collected$5422961492757.19M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRCPF vs ABBV ($10,000, DRIP)

YearBRCPF PortfolioBRCPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$26,481$15,780.93$11,550$430.00+$14.9KBRCPF
2$106,446$78,110.96$13,472$627.96+$93.0KBRCPF
3$700,781$586,884.32$15,906$926.08+$684.9KBRCPF
4$7,971,770$7,221,934.75$19,071$1,382.55+$7.95MBRCPF
5$162,087,710$153,557,915.24$23,302$2,095.81+$162.06MBRCPF
6$6,009,412,901$5,835,979,051.86$29,150$3,237.93+$6009.38MBRCPF
7$410,858,710,613$404,428,638,809.09$37,536$5,121.41+$410858.67MBRCPF
8$52,122,721,010,802$51,683,102,190,445.27$50,079$8,338.38+$52122720.96MBRCPF
9$12,311,224,407,242,836$12,255,453,095,761,274.00$69,753$14,065.80+$12311224407.17MBRCPF
10$5,423,826,956,248,914,000$5,410,653,946,133,164,000.00$102,337$24,771.77+$5423826956248.81MBRCPF

BRCPF vs ABBV: Complete Analysis 2026

BRCPFStock

BrasilAgro - Companhia Brasileira de Propriedades Agrícolas engages in the acquisition, development, exploration, and sale of rural properties suitable for agricultural activities in Brazil. The company operates through six segments: Real Estate, Grains, Sugarcane, Cattle Raising, Cotton, and Other. It is involved in the cultivation of soybean, corn, sorghum, and cotton, as well as sugarcane; and production and sale of beef calves after weaning. The company has 17 farms in 6 Brazilian states and 1 farm in Paraguay with a total area of 223,551 hectares of own lands and 51,747 hectares of leased lands. It also imports and exports agricultural products and inputs; purchases, sells, and/or rents properties, land, buildings, and real estate in rural and/or urban areas; provides real estate brokerage services; and manages third-party assets. The company was incorporated in 2005 and is headquartered in Sao Paulo, Brazil.

Full BRCPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BRCPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCPF vs SCHDBRCPF vs JEPIBRCPF vs OBRCPF vs KOBRCPF vs MAINBRCPF vs JNJBRCPF vs MRKBRCPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.